IBI3042

IBI3042 is a novel, oral, once-weekly small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist being developed by Innovent Biologics. It is designed for the treatment of metabolic disorders, specifically type 2 diabetes and obesity. Unlike first-generation GLP-1 therapies that require subcutaneous injection or daily oral administration, IBI3042 is engineered for once-weekly oral dosing, potentially offering significant improvements in patient convenience and adherence. As a small-molecule agonist, it activates the GLP-1 receptor to enhance glucose-dependent insulin secretion, suppress glucagon levels, and slow gastric emptying, thereby improving glycemic control and promoting weight loss.